Fractyl Health, Inc., a metabolic therapeutics company based in Burlington, MA, is committed to developing innovative solutions for obesity and type 2 diabetes (T2D). Despite advancements in treatment, these diseases continue to pose significant health risks. The company’s mission is to shift the focus of metabolic disease treatment from managing symptoms to providing long-lasting therapies that target the root causes of the diseases.
Fractyl Health recently announced that Dr. Harith Rajagopalan, CEO of the company, will be participating in a fireside chat at the upcoming BofA Securities 2024 Health Care Conference on May 15, 2024, at 4:20 p.m. PDT (7:20 p.m. EDT). To register for the webcast of the fireside chat, visit the company’s website.
For more information about Fractyl Health and their mission, visit their website or follow them on Twitter. For corporate inquiries, contact Lisa Davidson, Chief Financial Officer at ir@fractyl.com or 781.902.8800. For media inquiries, reach out to Beth Brett, Corporate Communications at bbrett@fractyl.com or 720.656.6544
